Morgan Stanley raised the firm’s price target on HCA Healthcare (HCA) to $425 from $400 and keeps an Equal Weight rating on the shares. Q3 results “underscore solid execution,” but “it may be time for a breather” following a strong run up in the stock, the analyst tells investors in a post-earnings note. With the stock up 30% since the Q2 report in late July, the stock could consolidate, though HCA is executing well and remains a bellwether in the group, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $525 from $444 at Cantor Fitzgerald
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc